Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age70+
SponsorOdense University Hospital

About this trial

The Improve study is a randomized controlled trial investigating the efficacy of adding comprehensive geriatric assessment and treatment to standard of care compared with standard of care in older, frail patients with hematological cancer. The investigators aim to recruit 152 study participants who will be randomized 1:1 to intervention- or control group. Study participants in the intervention group will receive the intervention comprehensive geriatric assessment and treatment integrated in the cancer treatment. Study participants in the control group will receive cancer treatment and evaluation of comorbidity and frailty as is usual standard at Department of Hematology. Primary endpoint is elderly functional Index at 12 weeks.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥70 years

New diagnosis or progression/relapse of acute leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, chronic myelomonocytic leukemia or myelofibrosis

Scheduled systemic cancer treatment or initiated systemic cancer treatment within 6 weeks

Geriatric 8 frailty score of ≤14 at screening

Disqualifiers

Current systemic treatment for other coexisting cancer. Patients receiving anti-hormone treatment for breast cancer or prostate cancer are not excluded, if no evidence of disease progression (radiological/biochemical) in past 3 months or if treatment is adjuvant.

Having consulted a geriatric outpatient clinic past 6 months

Patients in need of specialized neuro-rehabilitation

Unable to understand Danish

Trial design

Design model

Parallel

Treatments tested in this trial

  • Comprehensive geriatric assessment (CGA) and treatment

    Other intervention

    CGA and treatment is as an outpatient evaluation by a geriatric medical specialist and nurse. Specific CGA components in this study include: * Assessment of comorbidity and treatments * Review of medications including potential adjustment * Assessment of current symptoms and health related issues including geriatric syndromes such as depression, dementia, delirium, nutritional problems, falls and fatigue * Objective examination including blood tests and electrocardiogram * Assessment of activities of daily living (ADL) and instrumental ADL through standardized questionnaires * Assessment of domestic conditions, including need for assistance * Assessment of physical function Based on findings, the geriatrician will initiate relevant interventions and follow-up as required

Treatment groups

152 Participants
are divided into 2 treatment groups
Group A: Intervention armExperimental treatment 1 intervention
Group B: ControlNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Elderly functional Index

The Elderly Functional Index (ELFI) is calculated using the physical functioning, role functioning, and social functioning of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) core 30, and the mobility item of the EORTC-QLQ-elderly 14 (ELD14) questionnaire. ELFI is calculated at baseline and at 12- and 26- week follow-up. Maximum value of ELFI is 100. Minimum value of ELFI is 0. Higher score indicates higher function.

Time frame
12 and 26 weeks after inclusion

Secondary outcomes

1

European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).

The questionnaire contains functional and symptom subscales. Maximum value for scales is 100 and minimum values is 0. A higher score indicates higher function for functional scales and more symptoms for symptom scales.

Time frame
12 and 26 weeks after inclusion
2

European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Elderly14 (EORTC QLQ-Eld14).

The questionnaire contains functional scales and symptom scales. Maximum value for scales is 100 and minimum values is 0. A higher score indicates higher function for functional scales and more symptoms for symptom scales

Time frame
12 and 26 weeks after inclusion
3

Handgrip strength

Handgrip strength is measured in kilograms with a handgrip dynamometer

Time frame
12 and 26 weeks after inclusion
4

30-second chair stand test

30-second chair stand test is measured in number of stand-up-and-sit-downs in 30 seconds

Time frame
12 and 26 weeks after inclusion

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Odense University Hospital

Lead sponsor

Velux Fonden

Collaborator

Danish Cancer Research Foundation

Collaborator

The Dagmar Marshall Foundation

Collaborator